Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk by 42% in Phase 3 Trial

Results from the phase 3 INTerpath-001 trial, presented at the ESMO Congress 2026, indicate that adding the personalized mRNA-based cancer vaccine intismeran autogene to pembrolizumab after surgery for high-risk melanoma reduces the risk of recurrence or death by 42% compared with pembrolizumab alone. The study, led by Dr. Georgina Long of the Melanoma Institute Australia and The University of Sydney, evaluated the efficacy of this individualized therapy in patients who had undergone surgery for stage IIB–IV cutaneous melanoma. The trial randomly assigned 1,137 adults to receive either pembrolizumab plus intismeran or pembrolizumab plus a placebo. These findings represent the first phase 3 evidence that a treatment constructed from the unique molecular fingerprint of a patient’s own tumor can reduce the risk of recurrence or death.

Anti-PD-1 immunotherapy, such as pembrolizumab, is a standard treatment following surgery for high-risk melanoma, yet many patients still experience disease recurrence. Previous phase 3 trials that added a second checkpoint inhibitor to anti-PD-1 treatment failed to improve outcomes compared with anti-PD-1 therapy alone. Intismeran takes a different approach by leveraging the specific genetic mutations present in an individual’s tumor. Each patient’s tumor is sequenced to identify neoantigens, which are abnormal proteins specific to their cancer. Up to 34 of these neoantigens are encoded in mRNA to help the immune system recognize and attack any remaining cancer cells.

The risk of recurrence or death was assessed after a median follow-up period of 24.6 months. The data revealed a statistically significant benefit for the combination therapy, with a hazard ratio of 0.58 (95% confidence interval 0.45–0.75; p<0.001) favoring the addition of intismeran. At the two-year mark, 82.2% of patients receiving the combination therapy were alive without recurrence, compared with 70.0% of those receiving pembrolizumab alone. The trial also measured the risk of distant metastasis or death, finding a 38% reduction in this risk for the combination group (HR 0.62; 95% CI 0.45–0.85; p=0.002). Specifically, 88.5% of patients in the combination arm remained alive without distant metastasis at two years, versus 80.2% in the control arm. These benefits were observed consistently across both lower- and higher-risk disease subgroups.

While the recurrence-free survival data are compelling, the overall survival data at this interim analysis were not yet mature. The hazard ratio for overall survival was 0.77 (95% CI 0.45–1.31), which did not reach statistical significance. Dr. Long emphasized that longer follow-up is necessary to determine whether the observed reduction in recurrence translates into a definitive survival benefit. She noted that for patients, extending the time free of melanoma is a meaningful clinical benefit in its own right, but definitive conclusions regarding melanoma-specific and overall survival require more time. Longer follow-up is also needed to determine which specific patient subgroups derive the most benefit from the personalized approach.

The safety profile of the combination therapy was generally manageable, with the most common adverse events being fever and injection-site pain. Fever occurred in 52.2% of patients receiving the combination, compared with 8.2% in the placebo group, while injection-site pain was reported in 51.0% versus 9.5%. Fatigue was also more common in the combination group, affecting 38.5% of patients compared with 29.7% in the control group. Despite the higher incidence of these lower-grade side effects, the rate of severe adverse events, defined as grade 3 or higher, was similar between the two groups, occurring in 23.6% of the combination group and 20.3% of the placebo group. The side effects associated with the intismeran injections were described as generally low grade and transient.

Dr. Georgina Long, the lead author of the study, highlighted the innovative nature of the approach, describing the process as creating a “wanted poster” for the immune system. By sequencing the tumor, the therapy identifies the specific proteins that mark the cancer cells as foreign. This personalized mRNA vaccine then instructs the immune system to target these specific markers, enhancing the body’s natural defense mechanisms against residual disease. Long stressed that this is the first phase 3 study to demonstrate that a treatment built from the unique fingerprint of a patient’s own tumor can reduce the risk of recurrence or death.

Dr. James Larkin, Scientific Co-Chair of the ESMO Congress 2026 and not involved in the study, commented on the significance of the findings. He described the data from INTerpath-001 as a major advance for the adjuvant treatment of stage II and III melanoma, noting that the reduction in the risk of relapse is clinically significant. Larkin also praised the tolerability of the combination, stating that intismeran in combination with pembrolizumab is very well tolerated from a side-effect perspective.

Looking beyond melanoma, the researchers and experts highlighted the potential for this personalized mRNA vaccine approach to be applied to other types of cancer. Trials are already underway in lung, bladder, and kidney cancer to investigate whether similar benefits can be achieved in these malignancies. Dr. Larkin emphasized the importance of distinguishing this therapeutic approach from preventive vaccination. He clarified that this is not about vaccinating individuals without cancer to prevent disease development, but rather about treating existing cancer to prevent recurrence.

Subject of Research: Efficacy and safety of personalized mRNA vaccine intismeran combined with pembrolizumab in high-risk melanoma

Article Title: Personalized cancer vaccine plus immunotherapy reduces melanoma recurrence after surgery

Article References: Personalized cancer vaccine plus immunotherapy reduces melanoma recurrence after surgery. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: melanoma, mRNA vaccine, immunotherapy, pembrolizumab, intismeran, phase 3 trial, ESMO 2026, neoantigens, adjuvant therapy, cancer recurrence, Personalized, cancer